{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-129610","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2022-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.574515+00:00","generated_at":"2026-06-21T00:06:07.692519+00:00","sec_items":["1.01","2.03","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Outlook Therapeutics issues $31.82M convertible note to Streeterville; EMA accepts MAA for wet AMD","bullets":["Net proceeds ~$30M from $31.82M face convertible note at 9.5%, maturing Jan 1, 2024; repays $11.9M existing note.","Note convertible at $2.00/share; subject to 4.99% beneficial ownership cap (9.99% if market cap <$25M).","Company must raise $25M new equity to close; shareholder approval required for issuances above 45.2M share cap.","EMA validated MAA for ONS-5010 (bevacizumab-vikg) for wet AMD; EU decision expected early 2024.","U.S. FDA BLA accepted with PDUFA Aug 29, 2023; potential 8-year EU exclusivity, extendable to 10."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-129610","json":"https://secwatch.observer/filing/0001104659-22-129610.json","markdown":"https://secwatch.observer/filing/0001104659-22-129610.md","text":"https://secwatch.observer/filing/0001104659-22-129610.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465922129610/0001104659-22-129610-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465922129610/tm2233327d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T00:06:07.692519+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"48f5c7d06ae32630a977d15a871429e60638b0d9","claim":"Outlook Therapeutics, Inc. entered into Securities Purchase Agreement with Streeterville Capital, LLC valued at $31,820,000 unsecured convertible promissory note, reflecting an original issue discount of $1,800,0 (effective 2022-12-22).","evidence_excerpt":"On December 22 2022, Outlook Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (“SPA”) with Streeterville Capital, LLC, a Utah limited liability company (the “Lender”), and, pursuant to the SPA, issued to the Lender an unsecured convertible promissory note with a face amount of $31,820,000 (the “Note”), reflecting an original issue discount of $1,800,000, for gross proceeds of approximately $30 million after deducting the Lender’s transaction costs covered by the Company in connection with the issuance.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465922129610/0001104659-22-129610-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Value","value":"$31,820,000 unsecured convertible promissory note, reflecting an original issue discount of $1,800,0"},{"label":"Effective","value":"2022-12-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}